Podcasts about pharmd

In this episode, Thomas Carey, PharmD, Senior Director, Pharmacy Services, UW Northern Illinois, shares how the organization elevated its Med to Bed discharge program using multidisciplinary coordination, driving a nearly 30% reduction in 30-day readmissions. He also discusses agility in 340B compliance, leveraging learners, and the future of pharmacy growth through technology, automation, and workforce investment.

On this episode Fred Goldstein invites Steve Kheloussi, PharmD, MBA, FAMCP, Principal Consultant at Kheloussi Consulting, LLC, in the first installment of our four-part series on rare diseases. We discuss a practical overview of Duchenne muscular dystrophy (DMD), the current treatment landscape, and the evidence gaps that complicate payer decision-making. We also touch on the importance of what patients and caregivers need to maintain function, reduce fatigue, and navigate the significant emotional and practical burdens of care. This podcast is supported by an independent medical education grant from ITF Therapeutics. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please visit:  ⁠The Power of Partnership: Bridging Patients and Payers in Duchenne Muscular Dystrophy Management⁠. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

On this episode of Danatech Talks–a special series from The Huddle– Paola Acevedo, PharmD, CDCES, walks through how to simplify the process of prescribing diabetes technology. Paola discusses common pain points both clients and prescribers may face related to documentation, coverage and affordability, and accessibility. She also shares practical strategies, systems and workflows providers and practices can implement to help navigate through these potential challenges.This episode was supported by educational grant funding from Abbott.Explore the latest in diabetes technology as well as trainings and resources on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsExplore danatech's technology affordability tool: Diabetes Technology Affordability OptionsListen to previous episodes of our Danatech Talks diabetes technology series: https://thehuddle.simplecast.com/episodes/basics-diabetes-technology-for-health-care-professionalshttps://thehuddle.simplecast.com/episodes/understanding-cgms-and-interpreting-data-for-beginners  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 95 of Astonishing Healthcare features six previous guests on the show who share astonishing observations from 2025 and some bold predictions for the New Year! Industry veteran Jeffrey Hogan, our General Counsel and Chief Compliance Officer, Lloyd Fiorini, ERISA law expert Nick Welle, two of our clinical leaders – Sarra Izadi, PharmD, Chief Clinical Officer, and Bonnie Hui-Callahan, PharmD, CDCES, Sr. Director, Clinical Programs, and our Chief Technology Officer and Co-Founder, Ryan Kelly, joined us for this round-robin discussion that's packed with insightful reflections and optimism about the future. We won't ruin it in the show notes, but based on what we saw in 2025: Everyone has finally had enough of the costs and opacity of the U.S. healthcare system – a $70k family premium is truly astonishing It's surprising that, despite the lawsuits, warnings, and reform efforts, the proverbial hammer didn't drop on anyone for not being a good health plan fiduciary The speed and impact of AI have broadly been more positive than expected The rise of cardio-diabesity How GLP-1s helped shift the balance of power in the pharmaceutical supply chain And in 2026, we may see: Employers fight back – they take agency over their plans, and for first movers that started with transitioning to aligned PBMs, it's “game on” for the rest of their health plans The cash price – or acquisition cost – of drugs in the U.S. becomes the baseline – i.e., we finally see a real change in how drugs are priced ICHRAs and other alternative models become more popular Employers look to new clinical programs and models that demonstrate a return on their spending AI become more important for clinical workflows (not decision-making, at least not yet) Pharmaceutical manufacturers find themselves with increasing bargaining power vs. traditional PBMs A new Stanley Cup champion, and a Super Bowl ring for… Related Content Judi Health Policy Pulse: 2025 Regulatory Roundup, the Push for PBM Reform Replay - Unifying Medical and Pharmacy Benefits: The Blueprint for Better Employee Health and Wellness AH094 - How Unified Claims Processing Evolved from Pharmacy: Improving Member Care & Operating Efficiency Health Benefits 101: The Importance of Clinical Programs How to obtain Rx data and what to do with it For more information about Capital Rx and this episode, please visit Judi Health - Insights.

Listen in as our expert panel discusses evidence-based approaches to help patients quit smoking, vaping, and using other nicotine products. You'll gain practical insights on medication selection, combination strategies, and tailored approaches for helping patients break free from nicotine addiction.Special guest:Robin Corelli, PharmD, CTTS, FCSHPProfessor of Clinical PharmacySchool of PharmacyUniversity of California, San FranciscoYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in November 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Smoking Cessation Drug TherapyFAQ: E-Cigarettes and VapingChart: Dos and Don'ts With PatchesArticle: Help Patients Send Their Vaping Habits Up in Smoke Use code mt1026 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

Is ongoing hair loss more than just aging or genetics? More than 35 million men and 21 million women experience hair loss to some degree. Pharmacist and physician liaison, Bryana Gregory, takes a root-cause approach to understanding hair loss and hair regrowth. She explains how factors like hormonal imbalance, nutrient deficiencies, chronic stress, thyroid dysfunction, inflammation, and post-viral immune stress can disrupt the natural hair growth cycle and lead to excessive shedding. Hair loss is often the result of the body prioritizing survival over auxiliary functions like hair growth, especially during periods of prolonged inflammation.   Bryana introduces a proprietary compounded Hair Support Solution designed to address both hair loss and regrowth simultaneously. This topical formulation combines three synergistic ingredients to support circulation, collagen production, and follicle regeneration, and help reactivate dormant hair follicles. Together, these ingredients work locally at the scalp without systemic absorption, supporting healthier follicles and longer growth phases.   The episode also emphasizes the importance of supporting hair health through proper nutrition, adequate protein intake, stress management, and avoiding inflammatory hair products. Bryana explains how consistent topical use, combined with lifestyle awareness, can help restore balance at the follicular level. For those experiencing chronic hair thinning, post-COVID hair loss, or hormone-related shedding, this compounded solution offers a targeted, physician-guided option for addressing hair loss at its source.   Watch now and subscribe to our podcasts at www.HotzePodcast.com.   To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

In this episode, host Suzanne Feeney, PharmD, Senior Director, Pharmacy Solutions at McKesson Health Mart and guest Jaime Montuoro, PharmD, Director of Education & Practice Advancement at McKesson Health Mart, unpack two strategies you can deploy now: PGY1 community-based residencies and pharmacy credentialing. You'll learn how residency trained pharmacists can elevate clinical care in workflow, fuel change and help launch billable services. Then, we get practical on credentialing—why becoming “provider ready” matters and how claiming your team's Pharmacy Profiles credentials streamlines payer opportunities. Jaime shares real-world wins, including how Bryant Family Pharmacy partnered with a resident to implement prescriptive authority programs patients were willing to pay for. If you're ready to move beyond the transaction and build sustainable, community anchored care, this playbook will help you start today. HostSuzanne Feeney, PharmDSr. Director, Pharmacy Solutions McKesson / Health MartGuestJaime Montuoro, PharmDDirector, Education and Practice AdvancementMcKesson / Health MartResourcesTune into Episode 11: Maximizing Operations Through Proactive Workflow Health Mart Pharmacies can access Health Mart University (HMU) for:Health Mart pharmacists to claim their CE credit for weekly GameChangers episodesReferencesLearn more about the Health Mart Postgraduate Year One Community-based Pharmacy Residency Program herePharmacy Profiles is a pharmacy-friendly database that allows pharmacy teams to showcase their training and certifications in one place. If you're a Health Mart pharmacy demonstrate your pharmacy's readiness to receive potential patient care opportunities more quickly by having your pharmacy professionals claim their MYPROFILE. Learn more here: my.pharmacyprofiles.com. Pharmacy Profiles is a Strategic Health Alliance II, Inc., vendor.  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

On this episode, we discuss tobacco use disorder and describe its clinical impact, common presentations, and underlying neurobiological mechanisms. We evaluate current guidelines and evidence-based treatment strategies for smoking cessation, including pharmacologic and behavioral interventions. We also compare and contrast the efficacy, safety profiles, and appropriate use of nicotine-replacement therapies, prescription pharmacotherapies, behavioral strategies, and long-term patient follow-up in smoking cessation. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

We bring back our prior pharmacology discussion because it's so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!Content:- What are common drugs we use in "triplet regimens"? "quadruple therapy"? - What considerations must we take into account when prescribing commonly used medications in myeloma? - How should we counsel our patients? - What about supportive care?- How and when do we make dose adjustments? - This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not seeWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, our guest is Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and was chair ofthe Department of Pharmaceutical Sciences from 2003-2020. She was also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy. Her primary interests are in the treatment and pharmacogenetics of childhood leukemia and in the clinical implementation of pharmacogenetic testing in medicine. Dr. Relling is co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 450 original scientific manuscripts. She was elected to the Institute of Medicine (National Academy of Medicine) in 2009.Topics to discuss:Foundations & Career JourneyYou've had an extraordinary career at St. Jude since joining in 1988. What first drew you to pediatric pharmacology and pharmacogenetics?Your work has helped shape how we treat childhood leukemia. What do you see as the most transformative advancements in this space over your career?Pharmacogenetics & CPICYou co-founded the Clinical Pharmacogenetics Implementation Consortium (CPIC). What was the impetus behind its creation, and how has its mission evolved?What do you see as the biggest barriers to widespread clinical implementation of pharmacogenetic testing today?How do you respond to skepticism about the clinical utility of pharmacogenetic testing in everyday medical practice?Which pharmacogenetic guidelines do you believe have had the most significant clinical impact so far—and why?What advice do you have for institutions that want to start implementing pharmacogenetic testing but don't know where to begin?Implementation in Clinical SettingsAt St. Jude, you helped lead efforts to integrate pharmacogenetic testing into clinical care. What lessons did you learn about operationalizing this work in real-world settings?How important is interdisciplinary collaboration—between pharmacists, physicians, geneticists—in making pharmacogenetic testing work in practice?Can you share an example where pharmacogenetic testing changed the course of treatment for a pediatric patient?Policy, Ethics, and Future VisionWhat policy or regulatory changes would help accelerate the clinical adoption of pharmacogenetic testing?As someone who has contributed extensively to the science, how do you think we should balance data privacy with the need for clinical data sharing in genomics?What are you most excited about in the future of pharmacogenetics? Are there particular therapeutic areas or technologies that you think will drive the next wave of innovation?Legacy & AdviceYou've mentored many rising leaders in the field. What qualities do you think are most important for the next generation of pharmacogenomics researchers and clinicians?With over 450 publications and a career that has changed pediatric pharmacology, what legacy do you hope your work leaves behind?Guest: Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research HospitalHost: Hillary Blackburn, PharmD, MBAwww.hillaryblackburn.comhttps://www.linkedin.com/in/hillary-blackburn-67a92421/  ★ Support this podcast on Patreon ★

Matt and Paul recap top pearls from a recent episode on Anticoagulation for Venous Thromboembolism with Dr. Tara Lech, PharmD. They also answer listener questions and share their picks of the week.  Picks of the week: Paul Recommends: Death Stranding 2: On the Beach (videogame) Matt Recommends: CJ Box novels about Joe Picket

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes. Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma who progressed on at least 1 prior line of therapy.1 A significant progression-free survival benefit was observed with the experimental combination compared with standard of care in this population. They also discussed data from cohort A of the phase 2 IFM2021-01 trial (NCT05572229), which evaluated subcutaneous teclistamab in combination with subcutaneous daratumumab in patients with newly diagnosed multiple myeloma. Results demonstrated that the combination was effective and safe in the frontline treatment of patients who were ineligible for transplant.2 The discussion also covered the broader treatment landscape, as the experts compared the use of bispecific antibodies with BCMA-directed CAR T-cell therapies. Frontline bispecific strategies for transplant-ineligible populations were also topics of conversation, as well as post-transplant consolidation with bispecifics. Ultimately, they stated that multiple myeloma care is undergoing a paradigm shift toward deeper minimal residual disease negativity, possible treatment de‑escalation, and even serious use of the word “cure” for the disease. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center, and Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both are also members of the ASTCT content committee. References Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6 Manier S, Lambert J, Marco M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood. 2025;146(suppl 1):367. doi:10.1182/blood-2025-367

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

In this episode, Kuldip R. Patel, PharmD, FASHP, Senior Associate Chief Pharmacy Officer at Duke University Health System, discusses how pharmacy services are expanding across the continuum to reach more patients and improve outcomes. He shares insights on supply chain resilience, ambulatory and inpatient pharmacy growth, and the technologies shaping the future of pharmacy practice.

We bring back our prior pharmacology discussion because it's so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!Content:- What are common drugs we use in "triplet regimens"? "quadruple therapy"? - What considerations must we take into account when prescribing commonly used medications in myeloma? - How should we counsel our patients? - What about supportive care?- How and when do we make dose adjustments? - This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not seeWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, Sterling Elliott, PharmD, BCMTMS, Clinical Pharmacist Lead, Assistant Professor of Orthopaedic Surgery at Northwestern Medicine & Affiliate Faculty Member, Purdue University College of Pharmacy, shares how pharmacists are stepping into expanded leadership roles in ambulatory and procedural care amid rising cost pressures and the shift to value based care. He discusses opioid stewardship in orthopedic surgery, innovative patient education models, and the barriers and opportunities facing pharmacists practicing at the top of their license.

In this episode, our guest is Kate Campbell, PharmD, who serves as the Director of Pharmacy at Olympia Pharmacy. She is a proud alumna of the University of Florida, graduating Cum Laude with a bachelor's degree in biology and a doctorate in pharmacy. Dr. Campbell's previous work experiences in retail and hospital pharmacy have led to a passion for whole-person care and preventive medicine, prompting her shift towards compounding. In her pursuit, she has become a certified hormone replacement therapy specialist with a focus on bioidentical hormone replacement therapy for females.In her personal time, Kate loves connecting with her family and friends. She especially enjoys getting out on the water, playing pickleball and trying new restaurants.1. Opening & BackgroundKate, welcome to the show! Can you start by sharing your journey into pharmacy and what ultimately drew you toward compounding and personalized medicine?You've worked in both retail and hospital settings before moving into compounding—what gaps did you notice in traditional pharmacy that compounding helps to fill?How did your education at the University of Florida shape your path and perspective on whole-person care?2. Understanding Compounding & Regulatory LandscapeFor listeners who may not be familiar, can you explain the difference between 503A and 503B compounding pharmacies?What are some of the key compliance and quality distinctions between these two types of operations?Olympia Pharmacy operates under a 503B designation—what advantages does that provide in terms of scalability, safety, and product consistency?How do you see the role of compounding evolving as more patients seek individualized therapies?3. Hormone Replacement & Preventive MedicineYou're a certified hormone replacement therapy specialist, focusing on bioidentical hormones for women. What drew you to that niche?What are some of the biggest misconceptions about bioidentical hormone therapy?How do you personalize treatment for women across different stages of life—perimenopause, menopause, and beyond?What are the key questions women should ask their providers when considering hormone replacement therapy?4. Longevity & Wellness TrendsLongevity is becoming a buzzword in healthcare. From your vantage point, what longevity-focused products or therapies are worth the hype—and which are not?What innovations are you most excited about in the patient wellness space for the upcoming year?How is Olympia Pharmacy staying ahead of emerging trends—whether it's peptides, nootropics, or nutraceuticals?5. GLP-1s and Post-Therapy CareGLP-1 medications like semaglutide and tirzepatide have transformed weight management—but we're seeing challenges after patients discontinue them.What strategies or compounded therapies are helping patients maintain results post-GLP-1 use?How can pharmacists play a role in supporting metabolic health and sustainability beyond the initial weight-loss phase?6. Leadership, Lifestyle & Personal BalanceAs a director and pharmacist, how do you balance the science of pharmacy with the art of patient care?You've mentioned enjoying pickleball, the water, and exploring new restaurants—how do you recharge outside of work?What advice would you give to other pharmacists looking to explore nontraditional or entrepreneurial paths in pharmacy?7. ClosingWhat's next for you and Olympia Pharmacy?How can listeners connect with you or learn more about the services Olympia offers? ★ Support this podcast on Patreon ★

On this episode Fred Goldstein invites Sheena Crosby, PharmD, BCGP, Inflammatory Bowel Disease Clinical Pharmacist at the Mayo Clinic in Florida. Sheena breaks down the American College of Gastroenterology's (ACG) updated guidelines for ulcerative colitis and Crohn's disease, highlighting major shifts in treatment strategy, including the move toward earlier use of advanced therapies and updated goals focused on symptom control, mucosal healing, and sustained remission. She also outlines the critical payer considerations emphasized in the guidelines—from eliminating unnecessary step-therapy requirements to ensuring timely access to induction and maintenance therapy—changes that have direct implications for patient outcomes and health-system performance. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Kenric B. Ware, PharmD, MBA, AAHIVP, joined Over the Counter to discuss stigmas surrounding HIV care and prevention as well as the pharmacist's role in advancing management of the condition.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personalized, tumor-informed ctDNA assay; those testing positive for ctDNA were randomized to receive atezolizumab or placebo, while ctDNA-negative patients continued surveillance without treatment. The trial demonstrated significant improvements in both disease-free and overall survival in the atezolizumab group along with favorable outcomes among ctDNA-negative patients, suggesting many may safely avoid overtreatment. Joining Dr. Charles Turck to unpack the study results and how they highlight ctDNA's role in guiding personalized therapy is Dr. Andrea Necchi. Not only is he an investigator on this research, but he's also an Associate Professor of Oncology at Vita-Salute San Raffaele University and the Director of Genitourinary Medical Oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan, Italy.

Independent pharmacists are going beyond the counter to provide exceptional services through community partnerships. In this episode of The Counter Talk™ Podcast host Jason Callori speaks with Kristen Glesman, PharmD, Mandilyn Coffman, PharmD and Emily Rohling, PharmD.  These pharmacists share how they're transforming their pharmacies into vital community health destinations by partnering with local businesses and more . Hear from your peers on identifying opportunities, navigating challenges, and fostering a passionate team to drive innovation and growth.   

Dr. Ashley Dwyer, PharmD, joins Joe Drake to discuss why traditional dieting and cardio-heavy training stop working for women after 30. They cover protein intake, strength training, gut health, perimenopause, GLP-1 medications, and what women actually need to feel strong, lean, and healthy long term. A must-listen for trainers and women navigating hormonal changes.

Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer's disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer's models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer's care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFHProfessor of Pharmacy PracticeMidwestern University Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-25-375-H01-PInitial release date: 12/22/2025Expiration date: 12/22/2026Additional CPE details can be found here.

Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer's disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer's models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer's care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFHProfessor of Pharmacy PracticeMidwestern UniversityPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-25-375-H01-PInitial release date: 12/22/2025Expiration date: 12/22/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Medication mismanagement is one of the most costly and preventable problems in healthcare as it impacts patient safety, outcomes, and billions in annual spending. In this episode, we're joined by Yoona Kim, who cofounded Arine to use AI-driven medication intelligence for improving patient outcomes. Join us in a conversation about the key factors that contribute to medication errors, why culturally sensitive care is central to Arine's approach, and how smarter use of data can shape future healthcare policy.Yoona Kim is the co-founder and CEO of the healthcare technology company Arine. After studying human biology at Stanford, she was trained as both a pharmacist (PharmD from the University of California San Francisco) and health economist (PhD from the University of Texas at Austin). She previously served as Vice President at Proteus Digital Health and held leadership positions in research and consulting at global pharmaceutical companies.

On this episode of IPA's What, Why & How podcast, IPA CEO Matt Pitlick welcomes Anne Schlepphorst, Bureau Chief of Monitoring and Executive Director of the Iowa Board of Pharmacy, as well as Jillian (Jill) Kremmin, PharmD, BCPS, a compliance officer for northwest and western Iowa. Anne and Jill provide an update from the latest Board of Pharmacy meeting, specifically related to compounding. Connect with us on LinkedIn: Anne Schlepphorst Jillian Kremmin Matthew Pitlick Iowa Pharmacy Association

Independent pharmacists are going beyond the counter to provide exceptional services through community partnerships. In this episode of The Counter Talk™ Podcast host Jason Callori speaks with Kristen Glesman, PharmD, Mandilyn Coffman, PharmD and Emily Rohling, PharmD.  These pharmacists share how they're transforming their pharmacies into vital community health destinations by partnering with local businesses and more . Hear from your peers on identifying opportunities, navigating challenges, and fostering a passionate team to drive innovation and growth. 

In this episode, Mark Makhinson PharmD, Senior Director of Outpatient Pharmacy at Mount Sinai Health System, discusses how digital innovation, AI driven workflows, and a modern patient facing platform are reshaping specialty pharmacy, improving access, streamlining operations, and enhancing outcomes across the health system.

Blueprint: Evidence Over "Rearrangements and Vibes" — No “SN1 Rearrangement-like Policies”Guest: Dr. Oye Owolewa, PharmDGuest Bio United Sates Representative Oye Owolewa (D-D.C.) is a dedicated public servant and community advocate committed to uplifting the voices of underserved communities. Elected in 2020 as the U.S. Representative for the District of Columbia, Rep. Owolewa made history as the first Nigerian American elected to Congress. His leadership is rooted in a passion for equity, social justice, and empowering marginalized populations. Born to Nigerian immigrant parents, Rep. Owolewa grew up in Massachusetts before moving to Washington, D.C., where he earned his Doctorate in Pharmacy from Northeastern University. His background in healthcare has fueled his advocacy for accessible and affordable healthcare, mental health resources, and economic empowerment. Prior to his role in Congress, Rep. Owolewa actively served his community through various grassroots initiatives. He worked closely with local organizations to provide educational support, mentorship, and resources for D.C. residents. His focus on youth engagement and civic education has inspired young leaders to become active participants in their communities. In Congress, Rep. Owolewa continues to champion policies that promote racial and economic equity, expand mental health support, and address systemic injustices. He is a strong advocate for D.C. statehood, ensuring that residents of the nation's capital have full representation in Congress. His legislative priorities include economic development, healthcare awareness, and youth empowerment, aiming to create opportunities and resources for all D.C. residents. With a steadfast commitment to service, Rep. Owolewa remains dedicated to improving the lives of his constituents and building a more inclusive and just society for all. Episode Summary What happens when you apply mechanistic thinking—Woodward-level rigor and Percy Julian-level ingenuity—to public policy in Washington, D.C.? In this episode of Blueprint: Inventing the Future, we speak with Dr. Oye Owolewa, PharmD, who is running for DC City Council, exploring how clinical precision and evidence-based reasoning can translate into durable solutions for STEAM education, workforce development, digital equity, mental health, and civic empowerment. We frame D.C. governance like an organic synthesis problem: stabilize intermediates, control reaction conditions, eliminate “side reactions,” and design for yield—so opportunity is not theoretical, but repeatable. Music Credit Music: Reach The Top by Shane Ivers - https://www.silvermansound.com```

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Cogle, PharmD, BCNSP, FASPEN Evolving evidence supports the shift from single-source to multi-source intravenous lipid emulsions in parenteral nutrition. These newer formulations may offer improved metabolic, inflammatory, and hepatic outcomes, particularly for vulnerable patient populations. Joining Dr. Charles Turck to discuss the clinical rationale and operational considerations for these formulations is Dr. Sarah Cogle, who's a Clinical Pharmacist Specialist at Vanderbilt University Medical Center in Nashville, Tennessee.

In this encore episode of 'Relentlessly Seeking Value,' host Stacey Richter revisits an inspiring conversation with Marilyn Bartlett, a CPA who transformed the State of Montana's employee health plan from a $9 million deficit to a $112 million surplus within three years.  Known for her fiscal discipline and patient-first approach, Marilyn shares her strategic steps, from identifying waste in the system and securing quick wins to negotiating better deals with hospitals and ensuring long-term success. She emphasizes the importance of assembling a strong team, maintaining transparency, and staying focused on the ultimate goal of creating real health value. This episode is a must-listen for anyone looking to drive meaningful change in the healthcare industry. === LINKS ===

Tim Ulbrich, PharmD covers 10 practical year-end financial moves to reduce tax burden, build clarity, and start 2026 with confidence—plus a bonus step most people overlook. Episode Summary As 2025 winds down, it's tempting to push financial decisions into January. But some of the most impactful moves you can make happen before the calendar turns. In this episode, YFP Co-Founder & CEO Tim Ulbrich, PharmD walks through 10 practical, foundational financial moves to make before 2026 to help you reduce tax burden, invest with intention, organize your financial life, and enter the new year with clarity and momentum.  The episode wraps with a bonus step that isn't on most year-end checklists but may be one of the most leveraged decisions you can make heading into 2026: evaluating whether it's time to hire a financial planner or reassess your current advisory relationship. This is your financial "closing shift" for 2025—simple, intentional moves that quietly build confidence and long-term wealth. What you'll learn in this episode: How to perform a year-end financial inventory and why tracking net worth is one of the most powerful planning habits. Which tax-advantaged accounts need attention before December 31 and how to prioritize last-minute contributions. The importance of rebalancing your investment portfolio and prepare for paycheck changes heading into a new year. Why organizing estate documents, beneficiaries, and a "legacy folder" creates clarity and peace of mind. How to set meaningful financial goals for 2026 and evaluate whether it's time to hire (or reassess) a financial planner. Mentioned on the Show YFP Legacy Folder Checklist

In this special edition on Adherence to Medications our host, Dr. Neil Skolnik will discuss medication adherence and the role of clinicians, pharmacies and pharmacists in helping with medication adherence. This special episode is supported by an independent educational grant from Amazon. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Susan Kuchera, M.D. - Clinical Assistant Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington. Tess Carey, PharmD, Clinical Advisor for Amazon Pharmacy  Selected references: Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis. Journal of Cardiovascular Development and Disease. 2021, 8, 146. Adherence to antihypertensive medications for secondary prevention of cardiovascular disease events: a dose-response meta-analysis. Public Health 196 (2021) 179e185 Medication nonadherence - definition, measurement, prevalence, and causes: reflecting on the past 20 years and looking forwards. Frontiers in Pharmacology, March 2025. DOI 10.3389/fphar.2025.1465059  

Nuclear pharmacy is rapidly moving from the background to the forefront of oncology care.In this season finale episode, Nic Mastiscusa, PharmD, Chief Nuclear Pharmacist at the University of Iowa Hospitals and Clinics, breaks down how theranostics and radiopharmaceutical therapies are changing the way certain cancers are diagnosed and treated. Nick explains how targeted radioactive drugs can both locate tumors and deliver therapy, what this means for diseases like neuroendocrine tumors and prostate cancer, and why concepts such as alpha vs. beta emitters and dosimetry matter clinically.This episode is ACPE-accredited for pharmacists and pharmacy technicians and is worth 0.5 credit.Learning ObjectivesDescribe the role of nuclear pharmacy and theranostics in oncology careDifferentiate between diagnostic and therapeutic radiopharmaceuticalsExplain clinical differences between alpha- and beta-emitting radiopharmaceuticalsIdentify the role of dosimetry in personalized radiopharmaceutical treatmentRecognize key patient counseling and safety considerations related to radiopharmaceutical therapies CE InformationThis activity is ACPE accredited for pharmacists and pharmacy technicians.CE credit is available upon successful completion of the post-activity requirements.Access the CE activity here:https://www.lecturepanda.com/r/PQIPodcastTheranosticsCE DisclosuresNic Mastascusa, PharmD, R.Ph., BCNP discloses affiliations with NMTCB and NANP.

Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Jennifer Slaughter, ambulatory pharmacy supervisor at SSM Health Dean Medical Group, and her patient Debbie. Jennifer shares what inspired her to pursue a career in pharmacy and discusses the many paths within the profession, while Debbie offers her perspective as a patient and shares insights on the value of the pharmacist–patient relationship.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn N. Bulloch, PharmD, BCPS, FCCM, speaks with Olfa Hamzaoui, MD, PhD, professor of intensive care at Robert Debré Hospital in Reims, France, about her Peter Safar Honorary Lecture at the 2025 Critical Care Congress. The conversation centers on tissue perfusion, microcirculation, and shock, with a focus on bridging the gap between bench research and bedside practice. Dr. Hamzaoui shares insights on current scientific understanding of microcirculation and shock, including research on tools to monitor microcirculation, such as handheld video microscopy. The discussion highlights the utility of capillary refill time as a simple, noninvasive tool for guiding resuscitation. Dr. Hamzaoui advocates for early and repeated echocardiographic assessment in shock management, including during de-resuscitation. She also discusses her 2023 article in Clinical Medicine, which proposed titrating norepinephrine to individualized targets. This episode offers a compelling look at how emerging tools and research can refine shock management and promote precision care in critical illness. This podcast is sponsored by Fresenius Kabi. Resources referenced in this episode:  Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels Among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial (Zampieri FG, et al. Am J Respir Crit Care Med. 2020;201:423-429) The Eight Unanswered and Answered Questions about the Use of Vasopressors in Septic Shock (Hamzaoui O, et al. J Clin Med. 2023;12:4589) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 (Evans L, et al. Crit Care Med. 2021;49:e1063-e1143)

Quality Corner Show Host Nick Dorich, PharmD, welcomes back Richard Waithe, PharmD, COO of Pyrls, to discuss the integration of Pyrls with EQUIPP Copilot and how this can supercharge clinical pharmacy workflow.This episode focuses on how this powerful combination is helping pharmacists improve patient outreach, enhance consultations, and drive better health outcomes by dramatically improving access to essential drug information.

Melanie Dodd, PharmD, PhC, BCPS, FASHP, is the current President of the American Society of Health-System Pharmacists (ASHP) and the Associate Dean for Clinical Affairs and Professor at the University of New Mexico College of Pharmacy. Dr. Dodd talks through her priorities for ASHP this year, her involvement in the progressive New Mexico Society of Health-System Pharmacists, and her advice to those looking to get involved!

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen are joined by Aaron Sutton, LCSW, BCD, CAADC, to explore the unique challenges the holidays can bring when living with diabetes. They share practical strategies and offer guidance on how loved ones can provide meaningful support throughout the holiday season. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcastCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.  0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Episode Overview: In our inaugural This Week in Pharmacy, we examine the economic, technological, and policy-driven forces transforming pharmacy practice and the U.S. drug supply chain. From hidden financial power structures and AI-enabled operations to federal policy shifts impacting biosimilars, this episode brings together three timely conversations that every pharmacy leader should hear. Segment 1: The Hidden Lender in America's Drug Supply Chain Guests: Antonio Ciaccia, President, 3 Axis Advisors Alec Ginsberg, Founder, The Drugstore Cowboy Building on Alec Ginsberg's investigative article, “The Hidden Lender in America's Drug Supply Chain,” this discussion exposes how capital flows, credit structures, and opaque financial relationships influence pharmacy viability. Ciaccia and Ginsberg break down what independent pharmacists need to understand about who truly controls leverage in the system—and why transparency matters more than ever.   Segment 2: How AI Is Transforming Pharmacy Operations Guests: Harry Travis, BS Pharm, MBA, President, The Travis Group Amanda Awe, PharmD, Clinical Product Consultant, Curatio Advisors Artificial intelligence is no longer theoretical in pharmacy—it's operational. This segment explores how AI is being deployed today to improve workflow efficiency, clinical decision-making, and patient engagement, while addressing the real-world challenges of adoption. Segment 3: Policy Watch – IRA, Trump-Era Rx Changes & Biosimilars Guest: Jessica Daley, PharmD In this special policy-focused feature, Dr. Daley unpacks upcoming IRA-related developments and potential Trump-era prescription drug policy changes, with a sharp focus on how they could impact biosimilars and the U.S. supply chain. The conversation highlights what pharmacists should watch closely as regulatory and political pressures continue to evolve.   Inside the Forces Reshaping America's Drug Supply Chain | TWIRx    Thanks to NimbleRx, PRISM by OvaryIT, and Sykes & Company for sponsorsing today's show

Segment 1: The Hidden Lender in America's Drug Supply Chain Guests: Antonio Ciaccia, President, 3 Axis Advisors Alec Ginsberg, Founder, The Drugstore Cowboy Building on Alec Ginsberg's investigative article, “The Hidden Lender in America's Drug Supply Chain,” this discussion exposes how capital flows, credit structures, and opaque financial relationships influence pharmacy viability. Ciaccia and Ginsberg break down what independent pharmacists need to understand about who truly controls leverage in the system—and why transparency matters more than ever. Segment 2: How AI Is Transforming Pharmacy Operations Guests: Harry Travis, BS Pharm, MBA, President, The Travis Group Amanda Awe, PharmD, Clinical Product Consultant, Curatio Advisors Artificial intelligence is no longer theoretical in pharmacy—it's operational. This segment explores how AI is being deployed today to improve workflow efficiency, clinical decision-making, and patient engagement, while addressing the real-world challenges of adoption. Inside the Forces Reshaping America's Drug Supply Chain | TWIRx    Thanks to NimbleRx, PRISM by OvaryIT, and Sykes & Company for sponsorsing today's show

Every day, I hear patients share worries shaped by the growing wave of vaccine misinformation—questions that reveal just how overwhelming today's “infodemic” has become. In this podcast, I explore what vaccine hesitancy really looks like and how pharmacists can use empathy, strong recommendations, and meaningful dialogue to help rebuild confidence in immunization.Presenter:Mary Barna Bridgeman, PharmD, BCPS, BCGPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine Clinical Pharmacy SpecialistRobert Wood Johnson University Hospital-New BrunswickNew Brunswick, New JerseyLink to full program:https://bit.ly/4oHDWZqGet access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Community Leadership Award is a prestigious award recognizing our community pharmacists and their commitment to their patients. Each year at the Retail Business Conference (RBC), this award is presented to an independent pharmacist who demonstrates a commitment to promoting the principles of community pharmacy.                                                                                                                                                                             In this episode, Jason Callori speaks with finalist, Mike Burns, PharmD, AuBurn Pharmacies, on his advocacy efforts at the state and national level. Burns also discusses how his community involvements help him and his staff best serve their patients.

On this episode, we define major depressive disorder (MDD) and describe its clinical presentations, diagnostic criteria, etiologies, and pathophysiology. We also evaluate current guidelines and evidence-based treatment strategies for managing major depression, including pharmacological and nonpharmacological interventions. We then compare and contrast the efficacy, safety profiles, and appropriate use of antidepressant therapies, psychotherapy modalities, and adjunctive treatments in managing depression. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

Tim & Tim discuss how to handle a windfall or inheritance with clarity emotionally, financially, and strategically during the biggest wealth transfer in U.S. history. This episode is brought to you by the American Pharmacists Association (APhA). Episode Summary Handling a windfall or inheritance isn't just about the money—it's an emotional, relational, and identity-level shift. Whether it's an inheritance, equity payout, stock options vesting, or another financial surprise, the "right" next step can feel overwhelming. Many people think the challenge is how to invest a large sum… but the real challenge often begins much earlier: Who am I now that money is no longer the limiting factor? In this episode, Tim Ulbrich, PharmD, and Tim Baker, CFP®, RICP®, RLP® break down how to prepare for, navigate, and thoughtfully plan through sudden wealth. They talk about the emotional side of receiving money, how to avoid rushed decisions, the importance of building the right team, tax considerations, and how to align a windfall with your goals, values, and relationships. With the largest wealth transfer in U.S. history underway, this is a conversation every generation needs to hear. If you've received a windfall, expect one, or simply want to understand how to handle one wisely, this episode will help you slow down, think clearly, and make decisions you won't regret. What you'll learn in this episode: Why sudden wealth creates emotional, identity, and relational shifts—not just financial ones The most common types of windfalls and why they require different planning strategies How to avoid rushed decisions and use a "90-day pause" to regain clarity The key professionals you need on your team before making major moves How taxes, investment priorities, and giving strategies change when a windfall enters the plan Mentioned on the Show Mom and Dad, We Need to Talk by Cameron Huddleston Cerulli Associates "Great Wealth Transfer" data "Die With Zero" by Bill Perkins YFP Episode: 5 Key Questions to Ask Before Hiring a Financial Planner